Switching antiretroviral therapy from an enzyme-inducing drug.
Gyllensten
K
K
Department of Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Sweden.
Sönnerborg
A
A
Ståhle
L
L
D000328:Adult; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D019888:Nelfinavir / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019438:Ritonavir / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019562:Viral Load
D017320:HIV Protease Inhibitors; D019888:Nelfinavir; D019438:Ritonavir